Ketamine alters behavior and decreases BDNF levels in the rat brain as a function of time after drug administration

Revista Brasileira de Psiquiatria

Volumn 35, Issue 3, 2013, Pages 262-266

  Fraga, Daiane B ^a   Réus, Gislaine Z ^a   Abelaira, Helena M ^a   De Luca, Renata D ^a   Canever, Leila ^a   Pfaffenseller, Bianca ^b   Colpo, Gabriela D ^b   Kapczinski, Flávio ^b   Quevedo, João ^a   Zugno, Alexandra I ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Behavioral; Brain derived neurotrophic factor; Forced swimming test; Ketamine

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; KETAMINE;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CLIMBING; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED SWIMMING TEST; HIPPOCAMPUS; IMMOBILITY; LOCOMOTION; MALE; NONHUMAN; OPEN FIELD TEST; PREFRONTAL CORTEX; RAT;

AMYGDALA; ANESTHETICS, DISSOCIATIVE; ANIMALS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; KETAMINE; MALE; MOTOR ACTIVITY; PREFRONTAL CORTEX; RATS; RATS, WISTAR; SWIMMING; TIME FACTORS;

EID: 84885146686     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/1516-4446-2012-0858     Document Type: Article

References (40)

1. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann N Y Acad Sci. 2003;1003:318-27.
2. Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:140-4.
3. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, et al. Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry. 1999;156:1646-9.
4. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455-67.
5. Astur RS, Taylor LB, Mamelak AN, Philpott L, Sutherland RJ. Humans with hippocampus damage display severe spatial memory impairments in a virtual Morris water task. Behav Brain Res. 2002;132:77-84.
6. Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-Daspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856-64.
7. Engin E, Treit D, Dickson CT. Anxiolytic-and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models. Neuroscience. 2009;161:359-69.
8. Arlotta P, Magavi SS, Macklis JD. Induction of adult neurogenesis: molecular manipulation of neural precursors in situ. Ann N Y Acad Sci. 2003;991:229-36.
9. Harrison PJ. The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain. 1999;122:593-624.
10. Fisar Z, Hroudova J. Intracellular signalling pathways and mood disorders. Folia Biol (Praha). 2010;56:135-48.
11. Ichisaka S, Katoh-Semba R, Hata Y, Ohshima M, Kameyama K, Tsumoto T. Activity-dependent change in the protein level of brainderived neurotrophic factor but no change in other neurotrophins in the visual cortex of young and adult ferrets. Neuroscience. 2003;117:361-71.
12. Fumagalli F, Bedogni F, Perez J, Racagni G, Riva MA. Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur J Neurosci. 2004;20:1348-54.
13. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr Res. 2007;91:1-5.
14. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patientswith schizophrenia. Mol Psychiatry. 2003;8:592-610.
15. De Foubert G, Carney SL, Robinson CS, Destexhe EJ, Tomlinson R, Hicks CA, et al. Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment. Neuroscience. 2004;128:597-604.
16. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets. 2001;2:241-71.
17. Hunt MJ, Raynaud B, Garcia R. Ketamine dose-dependently induces high-frequency oscillations in the nucleus accumbens in freely moving rats. Biol Psychiatry. 2006;60:1206-14.
18. de Oliveira L, Fraga DB, De Luca RD, Canever L, Ghedim FV, Matos MP, et al. Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine. Metab Brain Dis. 2011;26:69-77.
19. Porsolt RD, Le Pichon M, Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature. 1977;266:730-2.
20. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
21. Irifune M, Shimizu T, Nomoto M. Ketamine-induced hyperlocomotion associated with alteration of presynaptic components of dopamine neurons in the nucleus accumbens of mice. Pharmacol Biochem Behav. 1991;40:399-407.
22. da Silva FC, do Carmo de Oliveira Cito M, da Silva MI, Moura BA, de Aquino Neto MR, Feitosa ML, et al. Behavioral alterations and prooxidant effect of a single ketamine administration to mice. Brain Res Bull. 2010;83:9-15.
23. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth. 1989;36:186-97.
24. Chaturvedi HK, Bapna JS, Chandra D. Effect of fluvoxamine and N-methyl-D-aspartate receptor antagonists on shock-induced depression in mice. Indian J Physiol Pharmacol. 2001;45:199-207.
25. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science. 1991;254:1515-8.
26. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351-4.
27. Liu F, Zou X, Sadovova N, Zhang X, Shi L, Guo L, et al. Changes in gene expression after phencyclidine administration in developing rats: a potential animal model for schizophrenia. Int J Dev Neurosci. 2011;29:351-8.
28. Danielyan A, Nasrallah HA. Neurological disorders in schizophrenia. Psychiatr Clin North Am. 2009;32:719-57.
29. Carlino D, Leone E, Di Cola F, Baj G, Marin R, Dinelli G, et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia. J Psychiatr Res. 2011;45:273-9.
30. Issa G, Wilson C, Terry AV, Jr., Pillai A. An inverse relationship between cortisol and BDNF levels in schizophrenia: data from human postmortem and animal studies. Neurobiol Dis. 2010;39:327-33.
31. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci Lett. 2005;382:27-32.
32. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci Lett. 2007;420:45-8.
33. Benjamin S, McQuoid DR, Potter GG, Payne ME, MacFall JR, Steffens DC, et al. The brain-derived neurotrophic factor Val66Met polymorphism, hippocampal volume, and cognitive function in geriatric depression. Am J Geriatr Psychiatry. 2010;18:323-31.
34. Kang H, Schuman EM. Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science. 1995;267:1658-62.
35. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients. Mol Psychiatry. 2000;5:293-300.
36. Takahashi M, Kakita A, Futamura T, Watanabe Y, Mizuno M, Sakimura K, et al. Sustained brain-derived neurotrophic factor upregulation and sensorimotor gating abnormality induced by postnatal exposure to phencyclidine: comparison with adult treatment. J Neurochem. 2006;99:770-80.
37. Hasbi A, Fan T, Alijaniaram M, Nguyen T, Perreault ML, O'Dowd BF, et al. Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth. Proc Natl Acad Sci U S A. 2009;106:21377-82.
38. Guo C, Yang Y, Su Y, Si T. Postnatal BDNF expression profiles in prefrontal cortex and hippocampus of a rat schizophrenia model induced by MK-801 administration. J Biomed Biotechnol. 2010;2010: 783297.
39. Hirota K, Lambert DG. Ketamine: its mechanism(s) of action and unusual clinical uses. Br J Anaesth. 1996;77:441-4.
40. Kozisek ME, Middlemas D, Bylund DB. Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther. 2008;117:30-51.